Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model - Scorecard - MDSpire
Advertisement
Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model
Clinical Scorecard: Impact of Combined Arylsulfatase B and Pembrolizumab Treatment on Metastatic Melanoma Progression in a B16F10 Syngeneic Mouse Model
At a Glance
Category
Detail
Condition
Key Mechanisms
Arylsulfatase B (ARSB) enhances apoptosis and reduces tumor progression through multiple signaling pathways, including modulation of PD-L1 expression.
Target Population
Care Setting
Key Highlights
highlight_4
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Assess apoptosis and cytokine expression in response to treatment.
Monitor for specific adverse effects such as immune-related adverse events.
Risks
Patient & Prescribing Data
Recombinant human ARSB is well-tolerated and shows significant clinical improvement, suggesting potential for human application.
